TNFRSF4 and neoplasm: Tumor-specific Tregs residing at the TME express high levels of CTLA-4 and OX40, and in situ injection of anti-CTLA-4 and anti-OX40 together with CpG can deplete tumor-infiltrating Tregs (104).